CoChat
Sign Up
Cited by 97Antifungal resistance and susceptibilityFungal Plant Pathogen ControlYeasts and Rust Fungi Studies

Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp

Open access
Messer, S. A., Diekema, D. J., Boyken, L., Tendolkar, S., Hollis, R. J., Pfaller, M. A.·2006·Journal of Clinical Microbiology
DOI 10.1128/jcm.44.2.324-326.2006PMC PMC1392702
Open this paper in CoChat — free account

Abstract

Micafungin is a new echinocandin exhibiting broad-spectrum activity against Candida spp. The activity of the echinocandins against Candida species known to express intrinsic or acquired resistance to fluconazole is of interest. We determined the MICs of micafungin and caspofungin against 315 invasive clinical (bloodstream and other sterile-site) isolates of fluconazole-resistant Candida species obtained from geographically diverse medical centers between 2001 and 2004. MICs were determined using broth microdilution according to the CLSI reference method M27-A2. RPMI 1640 was used as the test medium, and we used the MIC endpoint of prominent growth reduction at 24 h. Among the 315 fluconazole-resistant Candida isolates, 146 (46%) were C. krusei, 110 (35%) were C. glabrata, 41 (13%) were C. albicans, and 18 (6%) were less frequently isolated species. Micafungin had good in vitro activity against all fluconazole-resistant Candida spp. tested; the MICs at which 50% (MIC(50)) and 90% (MIC(90)) of isolates were inhibited were 0.03 microg/ml and 0.06 microg/ml, respectively. All the fluconazole-resistant Candida spp. were inhibited at a micafungin MIC that was </=1 microg/ml. Among the most common fluconazole-resistant Candida spp. tested in the collection, C. glabrata exhibited the lowest micafungin MICs (MIC(90), </=0.015 microg/ml), followed by C. albicans (MIC(90), 0.03 microg/ml) and C. krusei (MIC(90), 0.06 microg/ml). The new echinocandin micafungin has excellent in vitro activity against 315 invasive clinical isolates of fluconazole-resistant Candida, which represents the largest collection to date of fluconazole-resistant Candida isolates tested against micafungin. Micafungin may prove useful in the treatment of infections due to azole-resistant Candida.

Integrity signals

Registry

Crossref · 10.1128/jcm.44.2.324-326.2006

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Triazole-resistant clinical isolates and laboratory strains that demonstrate increased drug efflux pump expression remain susceptible to the echinocandins in laboratory liquid assays.

    “Triazole-resistant clinical isolates (Pfaller et al., 2005; Messer et al., 2006) and laboratory strains (Niimi et al., 2006) that demonstrate increased drug efflux pump expression remain susceptible to the echinocandins in laboratory liquid assays.”

    From Genetic Drivers of Multidrug Resistance in Candida glabrata (2016) · cites this paper as Messer et al., 2006

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Messer, S. A., Diekema, D. J., Boyken, L., Tendolkar, S., Hollis, R. J., & Pfaller, M. A.
Affiliations
  • Departments of Pathology
  • University of Iowa (US)
Corresponding author
Pfaller, M. A.
ORCID
Venue
Journal of Clinical Microbiology
Publisher
American Society for Microbiology
Published
2006-02
Volume
44
Issue
2
Pages
324-326
ISSN
  • 0095-1137 (ISSN-L)
  • 1098-660X
DOI
10.1128/jcm.44.2.324-326.2006
PMC
PMC1392702
OpenAlex
W2001506789
Cited by
97
References
21
Citations by year
2026: 1 · 2024: 1 · 2023: 2 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 3 · 2013: 2 · 2012: 7
FWCI
8.22
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Journal of Clinical Microbiology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Astellas Pharma
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
Keywords
micafungin, caspofungin, echinocandins, Candida glabrata, Candida albicans, Candida krusei, invasive candidiasis, antifungal susceptibility, minimum inhibitory concentration, azole resistance
MeSH terms
Micafungin, Antifungal Agents, Candida, Candidiasis, Humans, Lipoproteins, Microbial Sensitivity Tests, Peptides, Cyclic, Fluconazole, Drug Resistance, Fungal, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review